非小细胞肺癌患者化疗前后血浆D-二聚体测定的临床意义  

Clinical Significance of Non-small Cell Lung Cancer Patients Before and after Chemotherapy Plasma D-dimer

作　　者：王正东[1] 徐兴祥[1] 黄谦[1] 姚汉清[1] 

机构地区：[1]江苏省苏北人民医院呼吸科,扬州市225001

出　　处：《医药论坛杂志》2010年第20期26-27,30,共3页Journal of Medical Forum

摘　　要：目的检测非小细胞肺癌(NSCLC)患者血D-二聚体的改变,探讨肺癌患者在化疗前后D-二聚体指标变化的临床意义。方法采用胶体金方法测定60例NSCLC患者化疗前后血浆D-二聚体的含量。结果肺癌患者化疗前血浆D-二聚体水平显著高于对照组(P<0.05),化疗后D-二聚体含量显著低于化疗前(P<0.05)。结论 NSCLC患者早期就有血D-二聚体的异常升高,其异常改变对病情的发展、预后及疗效有重要意义,但不同病理类型肺癌的血D-二聚体水平无明显差异。Objective To determine the non-small cell lung cancer（NSCLC） patients with D-dimer change before and after chemotherapy in lung cancer patients D-dimer Indexes clinical significance.Methods Totally 60 cases of gold were determined before and after chemotherapy in NSCLC patients with plasma D-dimer levels.Results Patients with lung cancer before chemother-apy,plasma D-dimer levels were significantly higher（P 〈 0.05）.Conclusion The early stage NSCLC patients have abnormal blood D-dimer increased,its abnormal development of the disease,the prognosis and efficacy is important,but the different pathological types of lung cancer of the blood D-dimer levels were not significantly different.

关 键 词：非小细胞肺癌 化疗 D-二聚体 意义 

分 类 号：R734.2[医药卫生—肿瘤]